Stock ARAY ACCURAY INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Accuray Incorporated

Equities

ARAY

US0043971052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.185 USD +0.23% Intraday chart for Accuray Incorporated +2.10% -22.79%
Apr. 25 Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 CI
Apr. 18 Accuray Incorporated Expands Global Training Center Network with Opening of New Facility in Genolier, Switzerland CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 340.7 183.7 407.5 181.9 370.6 217.2 - -
Enterprise Value (EV) 1 423.7 265.5 407.5 181.9 370.6 217.2 217.2 217.2
P/E ratio -20.4 x 67.7 x -64.6 x -32.7 x -38.7 x -26.5 x 16.4 x 11.5 x
Yield - - - - - - - -
Capitalization / Revenue 0.81 x 0.48 x 1.03 x 0.42 x 0.83 x 0.47 x 0.44 x 0.42 x
EV / Revenue 0.81 x 0.48 x 1.03 x 0.42 x 0.83 x 0.47 x 0.44 x 0.42 x
EV / EBITDA 14.3 x 6.86 x 10.7 x 7.97 x 15.5 x 7.78 x 4.76 x 3.83 x
EV / FCF -10,033,380 x -36,552,383 x - - - - - -
FCF Yield -0% -0% - - - - - -
Price to Book 6.79 x 2.93 x - - - - - -
Nbr of stocks (in thousands) 88,024 90,517 90,161 92,802 95,752 99,169 - -
Reference price 2 3.870 2.030 4.520 1.960 3.870 2.190 2.190 2.190
Announcement Date 8/15/19 8/13/20 8/11/21 8/10/22 8/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 418.8 382.9 396.3 429.9 447.6 462.1 489.5 515
EBITDA 1 23.75 26.78 37.99 22.82 23.95 27.9 45.63 56.7
EBIT 1 4.792 11.87 22.24 8.148 2.382 10.79 26.77 30.15
Operating Margin 1.14% 3.1% 5.61% 1.9% 0.53% 2.33% 5.47% 5.85%
Earnings before Tax (EBT) 1 -14.34 5.019 -4.559 -2.002 -6.788 -5.66 16.03 21.05
Net income 1 -16.43 3.156 -6.311 -5.347 -9.28 -8.073 13.13 19
Net margin -3.92% 0.82% -1.59% -1.24% -2.07% -1.75% 2.68% 3.69%
EPS 2 -0.1900 0.0300 -0.0700 -0.0600 -0.1000 -0.0825 0.1333 0.1900
Free Cash Flow -33.95 -5.027 - - - - - -
FCF margin -8.11% -1.31% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/15/19 8/13/20 8/11/21 8/10/22 8/9/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 107.4 116.3 96.17 110 96.49 114.8 118.1 118.3 103.9 107.2 113.6 137.4 109.5 117 125.1
EBITDA 1 5.374 6.846 5.437 5.166 1.895 8.498 8.347 5.208 6.504 2.008 6.56 12.84 6 7.2 9.1
EBIT 1 2.411 3.981 -0.292 2.048 -2.182 2.705 2.316 -0.457 2.213 -3.964 4.067 9.404 2.7 3.7 5.3
Operating Margin 2.24% 3.42% -0.3% 1.86% -2.26% 2.36% 1.96% -0.39% 2.13% -3.7% 3.58% 6.85% 2.47% 3.16% 4.24%
Earnings before Tax (EBT) 1 -0.597 0.659 -0.639 -1.425 -5.108 -0.825 1.121 -1.976 -1.037 -8.743 -0.5542 6.079 0.7 1.6 3.2
Net income 1 -1.028 0.179 -1.046 -3.452 -5.449 -1.874 0.599 -2.556 -2.969 -9.621 -1.179 5.704 0.2 1.1 2.7
Net margin -0.96% 0.15% -1.09% -3.14% -5.65% -1.63% 0.51% -2.16% -2.86% -8.97% -1.04% 4.15% 0.18% 0.94% 2.16%
EPS 2 -0.0100 - -0.0100 -0.0400 -0.0600 -0.0200 0.0100 -0.0300 -0.0300 -0.1000 -0.0125 0.0600 - 0.0100 0.0300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/3/21 1/26/22 4/27/22 8/10/22 11/2/22 2/1/23 4/26/23 8/9/23 11/7/23 1/31/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 83 81.7 - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) 3.497 x 3.052 x - - - - - -
Free Cash Flow -34 -5.03 - - - - - -
ROE (net income / shareholders' equity) -33.4% 5.6% - - - - - -
ROA (Net income/ Total Assets) -4.02% 0.68% - - - - - -
Assets 1 408.5 464.1 - - - - - -
Book Value Per Share 0.5700 0.6900 - - - - - -
Cash Flow per Share - - - - - - - -
Capex 4.31 3.56 - - - - - -
Capex / Sales 1.03% 0.93% - - - - - -
Announcement Date 8/15/19 8/13/20 8/11/21 8/10/22 8/9/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Accuray Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.19 USD
Average target price
8.75 USD
Spread / Average Target
+299.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
ACCURAY INCORPORATED Stock Accuray Incorporated
-22.79% 217M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. ARAY Stock
  4. Financials Accuray Incorporated